Literature DB >> 7803484

Chemical and biological characterization of oxo-eicosatetraenoic acids.

J T O'Flaherty1, J F Cordes, S L Lee, M Samuel, M J Thomas.   

Abstract

Eicosatetraenoates (ETEs) with 5-oxo residues are known to induce human neutrophil (PMN) Ca2+ transients and chemotaxis. We find that 5-oxoETE, 5-oxo-8-trans-ETE, 5-oxo-15-hydroxy-ETE, 5-hydroxy-ETE, 5-hydroxy-15-oxoETE, 5,15-dioxoETE, and 5,15-dihydroxy-ETE have respective relative potencies of 10, 5, 3, 1, 0.2, 0.1, and 0.02 in: a) causing PMN to mobilize Ca2+, aggregate, and release small amounts of granule enzymes and b) promoting large degranulation and oxidative burst responses in PMN co-challenged with platelet-activating factor, tumor necrosis factor-alpha, or ATP. Contrastingly, 12(R)-hydroxy-ETE, 12(S)-hydroxy-ETE, and 12-oxoETE induced PMN Ca2+ transients and aggregation [respective potencies (5-hydroxy-ETE = 1) of 0.1, 0.01, and 0.003] but did not effect degranulation, and 15-hydroxy-ETE, 15-oxoETE, and 15-oxo-11-trans-ETE were inactive in all assays. Finally, 5-oxo/hydroxy-ETEs desensitized PMN to themselves but not to 12-oxo/hydroxy-ETEs or leukotriene (LT)B4; 12-oxo/hydroxy-ETEs and LTB4 desensitized PMN to themselves and each other but not to 5-oxo/hydroxy-ETEs; 15-oxo/hydroxy-ETEs did not desensitize PMN; and a LTB4 receptor antagonist blocked responses to LTB4 and 12-oxo/hydroxy-ETEs but not to 5-oxo/hydroxy-ETEs. Thus, 5-oxo/hydroxy-ETEs act by a common, LTB4 receptor-independent mechanism that recognizes 5- but not 12- or 15-oxo/hydroxy-ETEs and prefers oxo over hydroxy residues at C5 whereas 12-oxo/hydroxy-ETEs act via a LTB4 receptor mechanism that recognizes 12- but not 5- or 15-oxo/hydroxy-ETEs and prefers hydroxy over oxo residues at C12.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7803484     DOI: 10.1016/0304-4165(94)90083-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

1.  Inhibition of 5-oxo-6,8,11,14-eicosatetraenoic acid-induced activation of neutrophils and eosinophils by novel indole OXE receptor antagonists.

Authors:  Vivek Gore; Sylvie Gravel; Chantal Cossette; Pranav Patel; Shishir Chourey; Qiuji Ye; Joshua Rokach; William S Powell
Journal:  J Med Chem       Date:  2014-01-06       Impact factor: 7.446

Review 2.  The eosinophil chemoattractant 5-oxo-ETE and the OXE receptor.

Authors:  William S Powell; Joshua Rokach
Journal:  Prog Lipid Res       Date:  2013-09-19       Impact factor: 16.195

3.  5-oxo-15-HETE: total synthesis and bioactivity.

Authors:  Pranav Patel; Jaganmohan R Anumolu; William S Powell; Joshua Rokach
Journal:  Bioorg Med Chem Lett       Date:  2011-01-25       Impact factor: 2.823

Review 4.  Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid.

Authors:  William S Powell; Joshua Rokach
Journal:  Biochim Biophys Acta       Date:  2014-10-29

5.  Human CYP2S1 metabolizes cyclooxygenase- and lipoxygenase-derived eicosanoids.

Authors:  Peter Bui; Satoshi Imaizumi; Sudheer Reddy Beedanagari; Srinivasa T Reddy; Oliver Hankinson
Journal:  Drug Metab Dispos       Date:  2010-11-10       Impact factor: 3.922

Review 6.  5-Oxo-ETE and the OXE receptor.

Authors:  Gail E Grant; Joshua Rokach; William S Powell
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-05-18       Impact factor: 3.072

7.  5-oxo-ETE induces pulmonary eosinophilia in an integrin-dependent manner in Brown Norway rats.

Authors:  P Stamatiou; Q Hamid; R Taha; W Yu; T B Issekutz; J Rokach; S P Khanapure; W S Powell
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

8.  Fatty acid metabolites in rapidly proliferating breast cancer.

Authors:  Joseph T O'Flaherty; Rhonda E Wooten; Michael P Samuel; Michael J Thomas; Edward A Levine; L Douglas Case; Steven A Akman; Iris J Edwards
Journal:  PLoS One       Date:  2013-05-02       Impact factor: 3.240

9.  11-Oxoeicosatetraenoic acid is a cyclooxygenase-2/15-hydroxyprostaglandin dehydrogenase-derived antiproliferative eicosanoid.

Authors:  Xiaojing Liu; Suhong Zhang; Jasbir S Arora; Nathaniel W Snyder; Sumit J Shah; Ian A Blair
Journal:  Chem Res Toxicol       Date:  2011-09-30       Impact factor: 3.739

10.  Omega-3 Fatty Acids and PPARgamma in Cancer.

Authors:  Iris J Edwards; Joseph T O'Flaherty
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.